Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term Survival after Acute Myocardial Infarction: Comparison with Plasma Atrial Natriuretic Peptide and N-Terminal Proatrial Natriuretic Peptide

Circulation

Volumn 93, Issue 11, 1996, Pages 1963-1969

  Omland, Torbjørn ^a,e   Aakvaag, Asbjørn ^a   Bonarjee, Vernon V S ^b   Caidahl, Kenneth ^c   Lie, Rolv Terje ^a   Nilsen, Dennis W T ^b   Sundsfjord, Johan A ^d   Dickstein, Kenneth ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF TROMSØ   (Norway)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atrial natriuretic factor; Heart failure; Myocardial infarction; Peptides; Prognosis

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ENALAPRIL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; SYSTOLE;

AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CREATININE; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; LIFE TABLES; MALE; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; NORWAY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 0029948712     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.11.1963     Document Type: Review

References (54)

1. Tan AC, van Loenhout T, Lamfers EJ, Hooghoudt TE, Kloppenborg PW, Benraad TJ. Atrial natriuretic peptide after myocardial infarction. Am Heart J. 1989;118:490-494.
2. Jougasaki M, Yasue H, Mukoyama M, Nakao K, Takahashi K. Appearance of atrial natriuretic peptide in the ventricles in patients with myocardial infarction. Am Heart J. 1990;119:92-96.
3. Mukoyama M, Nakao K, Obata K, Jougasaki M, Yoshimura M, Morita E, Hosoda K, Suga S, Ogawa Y, Yasue H, Imura H. Augmented secretion of brain natriuretic peptide in acute myocardial infarction. Biochem Biophys Res Commun. 1991;180:431-436.
4. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, Mukoyama M, Nakao K. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993;88:82-91.
5. Arakawa N, Nakamura M, Aoki H, Hiramori K. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology. 1994;85:334-340.
6. Kettunen RV, Leppäluoto J, Jounela A, Vuolteenaho O. Plasma N-terminal atrial natriuretic peptide in acute myocardial infarction. Am Heart J. 1994;127:1449-1455.
7. Omland T, Aarsland T, Aakvaag A, Lie RT, Dickstein K. Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarction. Am J Cardiol. 1993;72: 255-259.
8. Omland T, Bonarjee VV, Nilsen DW, Sundsfjord JA, Lie RT, Thibault G, Dickstein K. Prognostic significance of N-terminal proatrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation. Br Heart J. 1993;70:409-414.
9. Hall C, Rouleau JL, Moyé LA, de Champlain J, Bichet D, Klein M, Sussex B, Packer M, Rouleau J, Arnold MO, Lamas GA, Sestier F, Gottlieb SS, Wun CC, Pfeffer MA. N-terminal proatrial natriuretic factor: an independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994;89:1934-1942.
10. Rouleau JL, Packer M, Moyé LA, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F, Parker JO, McEwan P, Bernstein V, Cuddy TE, Lamas G, Gottlieb SS, McCans J, Nadeau C, Delage F, Wun CC, Pfeffer MA. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24: 583-591.
11. Omland T, Bonarjee VV, Lie RT, Caidahl K. Neurohumoral measurements as indicators of long-term prognosis after myocardial infarction. Am J Cardiol. 1995;76:230-235.
12. Remes J. Neuroendocrine activation after myocardial infarction. Br Heart J. 1994;72(suppl 3):65-69.
13. Nakao K, Mukoyama M, Hosoda K, Suga S, Ogawa Y, Saito Y, Shirakami G, Arai H, Jougasaki M, Imura H. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol. 1991;69:1500-1506.
14. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H, Kambayashi Y, Inouye K, Imura H. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402-1412.
15. Arakawa N, Nakamura M, Aoki H, Moriai N, Suzuki T, Hiramori K. Prognostic value of plasma brain natriuretic peptide concentration in patients with acute myocardial infarction. Circulation. 1994;90(part 2):I-279. Abstract.
16. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H, on behalf of the CONSENSUS II study group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med. 1992;327:678-684.
17. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol. 1967;20:457-464.
18. Omland T, Barvik S, Aakvaag A, Aarsland T, Dickstein K. Plasma atrial natriuretic factor concentration during maximal cardiopulmonary exercise in men with mild heart failure. Int J Cardiol. 1990;29: 179-184.
19. Sundsfjord JA, Thibault G, Larochelle P, Cantin M. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab. 1988;66:605-610.
20. Kono M, Yamauchi A, Tsuji T, Misaka A, Igano K, Ueki K, Fujishima M, Ueda A, Inouye K, Nakao K, Imura H. An immunoradiometric assay for brain natriuretic peptide in human plasma. Kaku Igaku Gijutsu. 1993;13:2-7.
21. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90: 195-203.
22. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab. 1993;76:832-838.
23. Schiller NB, Shah PM, Crawford M, DeMaria A, Deveraux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik AJ. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
24. Bonarjee VV, Carstensen S, Caidahl K, Nilsen DW, Edner M, Berning J. Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. Am J Cordiol. 1993;72:1004-1009.
25. Hopkins A. Survival analysis with covariates. In: Dixon WJ, ed. BMDP Statistical Software Manual. Berkeley, Calif: University of California Press; 1990:769-806.
26. Benedetti J, Yuen K, Young L. Life tables and survivor functions. In: Dixon WJ, ed. BMDP Statistical Software Manual. Berkeley, Calif: University of California Press; 1990:739-768.
27. Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for angiotensin-converting enzyme inhibition after myocardial infarction. Lancet. 1993;341: 1109-1113.
28. Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H, Nicholls MG. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J. 1993;69:414-417.
29. Haug C, Metzele A, Kochs M, Hombach V, Grünert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol. 1993;16:553-557.
30. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, Nakao K, Imura H. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993;87:464-469.
31. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
32. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau L, Rouleau JL, Rutherford JR, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
33. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI 3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343: 1115-1122.
34. Fourth International Study of Infarct Survival Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet. 1995; 345:669-685.
35. Struthers AD. Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use? BMJ. 1994;308: 1615-1619.
36. Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM, Burnett JC Jr. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet. 1993;341:1105-1109.
37. Choy AM, Darbar D, Lang CC, Pringle TH, McNeill GP, Kennedy NS, Struthers AD. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J. 1994;72:16-22.
38. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med. 1983;309: 331-336.
39. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S, Menapace FJ Jr, Parker JO, Lewis S, Sestier F, Gordon DF, McEwan P, Bernstein V, Braunwald E. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: the protective effects of captopril. Circulation. 1994;89:68-75.
40. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriurctic peptide in patients with chronic heart failure. J Am Coll Cardiol. 1989;13:1534-1539.
41. Svanegaard J, Angelo-Nielsen K, Pindborg T. Plasma concentration of atrial natriuretic peptide at admission and risk of cardiac death in patients with acute myocardial infarction. Br Heart J. 1992;68: 38-42.
42. Mathisen P, Hall C, Simonsen S. Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. Scand J Clin Lab Invest. 1993;53:41-49.
43. Hosoda K, Nakao K, Mukoyama M, Saito Y, Jougasaki M, Shirakami G, Suga S, Ogawa Y, Yasue H, Imura H. Expression of brain natriuretic peptide gene in human heart: production in the ventricle. Hypertension. 1991;17:1152-1155.
44. Sumida H, Yasue H, Yoshimura M, Okumura K, Ogawa H, Kugiyama K, Matsuyama K, Kikuta K, Morita E, Nakao K. Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J Am Coll Cardiol. 1995;25:1105-1110.
45. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation. 1990;81:1161-1172.
46. Mäntymaa P, Vuolteenaho O, Martilla M, Ruskoaho H. Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro. Endocrinology. 1993;133:1470-1473.
47. Maack T, Suzuki M, Almeida FA, Nussenzveig R, Scarborough GA, McEnroc GA, Lewicki JA. Physiological role of silent receptors of atrial natriuretic factor. Science. 1987;238:675-678.
48. Okolicany J, McEnroe GA, Koh GY, Lewicki JA, Maack T. Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor. Am J Physiol. 1992;263:F546-F553.
49. Brandt RR, Redfield MM, Aarhus LL, Lewicki JA, Burnett JC Jr. Clearance receptor-mediated control of atrial natriuretic factor in experimental congestive heart failure. Am J Physiol. 1994;266: R936-R943.
50. Lang CC, Motwani JG, Coutie WJ, Struthers AD. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clin Sci (Colch). 1992;82:619-623.
51. 2-terminal fragment of rat proatrial natriuretic factor in the circulation: identification, radioimmunoassay and half-life. Peptides. 1988;9:47-53.
52. Ngo L, Vesely DL, Bissett JK, Murphy ML, Dinh H, Sallman AL, Rico DM, Winters CJ, Wyeth RP. Acute and sustained release of the atrial natriuretic factor prohormone N-terminus with acute myocardial infarction. Am J Med Sci. 1991;301:157-164.
53. Davidson NC, Coutie WJ, Struthers AD. N-terminal proatrial natriuretic peptide and brain natriuretic peptide are stable for up to 6 hours in whole blood in vitro. Circulation. 1995;91:1276. Letter.
54. Hall C, Aaberge L, Stokke O. In vitro stability of N-terminal proatrial natriuretic factor in unfrozen samples: an important prerequisite for its use as a biochemical parameter of atrial pressure in clinical routine. Circulation. 1995;91:911. Letter.